NEW YORK--(BUSINESS WIRE)--June 12, 2006--Bioenvision, Inc. (NASDAQ: BIVN - News) today announced that following selection by the European Hematology Association (EHA), data on it's Evoltra(TM) (clofarabine) in adult acute myeloid leukemia (AML) will be presented as a poster presentation at the EHA's 11th Annual Congress in Amsterdam. The EHA's congress is a leading hematology conference in Europe and this year a record number of abstracts were submitted for review by the EHA's Scientific Program Committee.
